Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib

Autor: Lankheet, N.A.G., Desar, I.M.E., Mulder, S.F., Burger, D.M., Kweekel, D.M., Herpen, C.M.L. van, Graaf, W.T.A. van der, Erp, N.P. van

Publikováno v: British Journal of Clinical Pharmacology, 83, 2195-2204
British Journal of Clinical Pharmacology, 83, 10, pp. 2195-2204
British Journal of Clinical Pharmacology, 83(10), 2195-2204

Item does not contain fulltext AIM: Fixed dose oral tyrosine kinase inhibitors imatinib, sunitinib and pazopanib show a high interpatient variability in plasma exposure. A relationship between plasma exposure and treatment outcome has been establishe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::683e9dab8c3fb42921438360a34b817b
https://doi.org/10.1111/bcp.13327

Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature

Autor: ter Heine, R., van den Bosch, R.T.A., Schaefer-Prokop, C.M., Lankheet, N.A.G., Beijnen, J.H., Staaks, G.H.A., van der Westerlaken, M.M., Malingré, M.M., van den Brand, J.J.G.

Publikováno v: In Lung Cancer March 2012 75(3):391-397

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1678P - Predictive Value of Two Phenotyping Probes for the Pharmacokinetics of Sunitinib in Cancer Patients

Autor: Kloth, J.S.L., Klumpen, H.J., Samer, C.F., Eechoute, K., Lankheet, N.A.G., Kam, B.L., Wong, M., Schellens, J.H.M., Mathijssen, R.H.J., Gurney, H.

Publikováno v: In Annals of Oncology September 2012 23 Supplement 9:ix538-ix538

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.